help_outline Skip to main content
Shopping Cart
cancel
Add Me To Your Mailing List
Organization of Regulatory and Clinical Associates
Contact Information:
Organization of Regulatory and Clinical Associates
P.O. Box 3490
Redmond, WA 98073
HomeCurrent/Future EventsWEBINAR - Efficacy of Doxycycline in Post-exposure Prophylaxis of Bacterial STIs

Current/Future Events - Event View

This is the "Event Detail" view, showing all available information for this event. If registration is required or recommended, click the 'Register for Webinar' button to start the process. If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.

WEBINAR - Efficacy of Doxycycline in Post-exposure Prophylaxis of Bacterial STIs

When:
Thursday, October 20, 2022, 8:00 AM until 10:00 AM
Additional Info:
Event Contact(s):
ORCA Admin
Category:
Webinar
Registration is required
Payment In Full In Advance Only
RSVP by 9:00PM Wednesday, October 19, 2022

Meetings and webinars are scheduled on Pacific Standard Time or Pacific Daylight Time, whichever applies.

Please make sure that the following email address is in your Safe Sender list: mailer@mail2.clubexpress.com. System messages like meeting announcements, registration confirmations, webinar login instructions as well as certificates of attendance are sent directly from this email address.

You will receive the webinar login instructions in an email 2 days prior to the meeting date, or the night prior to the meeting if registering closer to the event. If you don't receive the instructions within this time frame, please contact us at info@orcanw.org as soon as possible.

PAID FEES ARE NON REFUNDABLE.

For webinar events, payment is REQUIRED at the time of registration.
Capacity:
100
No Fee
$60.00

TOPIC: Efficacy of Doxycycline in Post-exposure Prophylaxis of Bacterial Sexually Transmitted Infections (STIs) - Clinical Trial

TOPIC DESCRIPTION: DoxyPEP is a randomized open label clinical trial to determine if taking an antibiotic called Doxycycline after sex (i.e. post-exposure prophylaxis or PEP) prevents bacterial sexually transmitted infections (STIs) - specifically syphilis, chlamydia and gonorrhea- among men who have sex with men and transgender women living with HIV or on PrEP. The study was conducted in 4 clinical sites in San Francisco and Seattle. The control arm was stopped in May 2022 after the study met prespecified efficacy thresholds. The study design and findings will be summarized.

SPEAKER: Connie L. Celum

SPEAKER BIOGRAPHY: Connie Celum, MD, MPH, is Professor of Global Health, Medicine, and Epidemiology, and Director of the International Clinical Research Center at the University of Washington. She is an infectious disease physician, epidemiologist, and clinical researcher. Her research interests focus on HIV prevention strategies, including HIV pre-exposure prophylaxis and prevention and treatment of sexually-transmitted infections. She has led multi-center HIV prevention efficacy trials, including genital herpes suppression for prevention of HIV acquisition as well as HIV transmission. She co-led the Partners PrEP Study, which demonstrated high efficacy of tenofovir and emtricitabine-tenofovir prophylaxis, which contributed to FDA approval of PrEP for HIV prevention. Currently Dr. Celum's research is focusing on implementation science research about PrEP implementation and STI interventions for young African women and MSM in the US. She is the co-Principal Investigator for the DoxyPEP study to evaluate doxycycline post-exposure prophylaxis for MSM and TGW living with HIV and on PrEP.

WHO: Clinical, regulatory, quality, manufacturing and legal

Attendance at this meeting may be applied as 1.5 points towards RAC re-certification

All attendees must be registered. Access to education content is a benefit of membership or guest attendance. The link to the webinar is intended for the registered person ONLY and any access/distribution of materials beyond the individual registrant is strictly prohibited. Viewing rights are not transferable and cannot be combined by multiple parties without express permission. Thank you for your understanding.
This webinar will NOT be recorded.